Endovasc Receives Notice of Allowance for U.S. Patent Protecting Its Muscle Mass Technology.
"This patent adds a new layer to our Company's broad intellectual property portfolio and demonstrates Endovasc's innovation in the field of nutraceuticals. We are committed to commercializing our pipeline of nutraceutical products. Patent protection such as this is critical for ensuring Endothil-CR's exclusivity in the marketplace," said Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer.
Endovasc's wholly owned subsidiary, Nutraceutical Development Corporation (NDC), licensed the technology to Basic Research to develop and market a non-steroid supplement which utilizes the Company's muscle mass technology. Endothil-CR is currently available at GNC stores nationwide or on the World Wide Web at www.Endothil.com.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation.
For more information about Endovasc, please visit www.endovasc.com.
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.